Apellis Pharmaceuticals, Inc. (APLS)

WALTHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a ... Read More

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a ... Read More

Apellis Pharmaceuticals Inc (APLS) Stock: What the Analysts are Saying

Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for APLS is 98.84M, and at present, short sellers hold a 10.56% ... Read More

Latest News for Apellis Pharmaceuticals Stock (NASDAQ:APLS)

Citron Research Posts On X, "$APLS Expect A Raise Soon. Not Getting European Approval Shows How Dysfunctional Our Healthcare System Is. Citron Stands By Our Report ... Read More

Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?

Will the recent negative trend continue leading up to its next earnings release, or is Apellis Pharmaceuticals due for a breakout? Before we dive into how investors and analysts have reacted as of ... Read More

Apellis Pharmaceuticals Hold Rating: Navigating Syfovre’s Mixed Reception and Emerging Competition

Analyst Graig Suvannavejh of Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price target of $60.00. Graig Suvannavejh has given his ... Read More

Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals

Apellis Pharmaceuticals (NASDAQ:APLS) has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates ... Read More

Apellis Pharmaceuticals Stock (NASDAQ:APLS), Quotes and News Summary

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Top ... Read More

Apellis Pharmaceuticals Inc.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ... Read More

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical ... Apellis Forward-Looking Statement Statements in this press release about future expectations, plans and prospects, as well ... Read More

Apellis Pharmaceuticals Inc.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ... Read More